Producing instant diagnostic results

anywhere by anyone.


learn more

our mission

Phase Diagnostics’ focus is to develop next generation rapid point-of-care (POC) diagnostic kits for major unmet testing needs.
Our platform diagnostic technology offers solutions for an array of clinical and consumer applications.
  • Connector.

    Unprecedented accuracy

    Bridging the gap between lab-based performance and rapid diagnostic testing

  • Connector.

    One-step, inexpensive, and fast

    Less than 20 minutes, No required capital equipment, training, or power supply

  • Connector.

    Unlimited potential applications

    Proprietary technology based on the intrinsic ability to enable seamless concentration and detection of target biomarkers, adaptable to a vast range of testing needs

SUPPORT FROM
 

“Phase Diagnostics’ technology utilizes cutting edge paper microfluidics to enable unprecedented reliability at the point-of-care and at home”

“Phase Diagnostics’ technology utilizes cutting edge paper microfluidics to enable unprecedented reliability at the point-of-care and at home”

impact on a global scale

Dental Caries

affects
0%
of population at some point in life

Enabling reliable and objective tests for caries prevention

Dental caries, also known as tooth decay or cavities, is the most common oral disease across the globe, affecting 92% of the population at some point in their lifetime.

71% of all restorative treatments are performed on previously restored teeth indicating that the root cause is not addressed.

Personalized preventative care be achieved through proper detection and monitoring of caries risk factors.


Increasing screening access by lowering barriers for testing

Chlamydia (Chlamydia trachomatis, CT) and gonorrhea (Neisseria gonorrhea, NG) comprise the leading group of reportable diseases in the United States.

An estimated 4 million new cases occur each year with less than 40% of the CDC recommended testing performed. There is an urgent public health need for faster and cheaper CT/NG screening methods.


Sexually Transmitted Infection

less than
0%
recommended CT/NG screenings are actually performed


Sexually Transmitted Infection

less than
0%
recommended CT/NG screenings are actually performed

Increasing screening access by lowering barriers for testing

Chlamydia (Chlamydia trachomatis, CT) and gonorrhea (Neisseria gonorrhea, NG) comprise the leading group of reportable diseases in the United States.

An estimated 4 million new cases occur each year with less than 40% of the CDC recommended testing performed. There is an urgent public health need for faster and cheaper CT/NG screening methods.


Malaria

approximately
0%
of people live in malaria-endemic regions

Providing better tools towards disease elimination

Approximately half of the world’s population lives in malaria-endemic regions with an estimated 219-515 million new malaria cases and 660,000-1,238,000 deaths due to malaria each year.

Eradication of malaria requires effective and inexpensive diagnostics to identify and treat infected patients. However, current rapid diagnostic technologies lack the requisite sensitivity and access.

other applications

defense

food safety

home care

environmental

other applications

defense

food safety

home care

environmental

recent news


  • April 2017 NSF Phase II grant awarded

    Phase Diagnostics is proud to receive the $750k Phase II grant award from the National Science Foundation. The funding will enable us to further develop our rapid point-of-care test for Chlamydia trachomatis towards commercialization.

  • March 2017 NIH Phase I/II Fast Track grant awarded

    Phase Diagnostics is proud to receive the $1.15 million Phase I/II Fast Track grant award from the National Institutes of Health. The funding will enable us to further develop our rapid point-of-care test for Chlamydia trachomatis towards commercialization.

  • November 2016 Bill and Melinda Gates Foundation grant awarded

    Phase Diagnostics is very excited to announce our Bill and Melinda Gates Foundation Grand Challenges award. The $100k funding will allow us to apply our technology in developing a saliva-based rapid point-of-care test for malaria that is fully integrated and does not require equipment, power or trained technicians.

  • November 2015 NSF Phase I grant awarded

    Phase Diagnostics is proud to receive the $150k Phase I grant award from the National Science Foundation. The funding will allow us to investigate the development of a novel, one step rapid point-of-care (POC) diagnostic for Chlamydia trachomatis (CT) infection.

the team

Dr. Ricky Chiu

CEO and Co-founder

Dr. Ricky Chiu is the co-founder and CEO of Phase Diagnostics. He is the lead inventor of Phase Diagnostics’ platform technology, which was based on his Ph.D. work. He was formerly at BMC (acquired by Alere Inc.,) where he took several rapid POC diagnostics from concept to market. Dr. Chiu received his PhD in bioengineering at the University of California, Los Angeles.

Dr. Garrett Mosley

COO and Co-founder

Garrett Mosley, PhD is the co-founder and COO Phase Diagnostics. He co-invented Phase Diagnostic’s core technology and worked on modifying the diagnostic design for over-the-counter use. He received his PhD in bioengineering at the University of California, Los Angeles

Felix Chao

Director of Operations and Business Development

Felix Chao is the Director of Operations and Business Development at Phase Diagnostics. He was the former Head of Project Management at SciClone Pharmaceuticals (NYSE:SCLN), a global spec-pharma company with revenues over $150 million. He received his B.S. in Bioengineering from the University of California, Los Angeles.

Brian Lee

Research Associate

Brian Lee is a Research Associate at Phase Diagnostics. He was a former process engineer at Baxalta where he supported manufacturing and capital projects. Brian received his M.S. and B.S. in bioengineering at the University of California, Los Angeles.

Beatrice Lim

Research Associate

Beatrice Lim is a Research Associate at Phase Diagnostics. She received her M.S. in physiology and biophysics from Georgetown University and her B.S. in biological sciences and B.A. in psychology from the University of California, Irvine.

our advisory board

Dr. Ben Wu

Co-founder and Advisor

Dr. Ben Wu is a co-founder and advisor of Phase Diagnostics. He is the Chair and Professor in the Department of Bioengineering at UCLA with joint academic appointments in the Department of Materials Science and Engineering and the School of Dentistry. Dr. Wu is a co-founder of multiple startups and is on the scientific advisory boards of 4 other companies, providing expertise on biomaterials processing, characterization, and clinical usage.

Dr. Daniel Kamei

Co-founder and Advisor

Dr. Daniel Kamei is the Vice Chair and Associate Professor in the UCLA Department of Bioengineering. He is the pioneer of Phase Diagnostics’ technology. His work has led to multiple peer-reviewed publications that have significantly impacted the development of the Phase Diagnostics platform technology.

Dr. Jeffrey Klausner

Advisor

Dr. Jeffrey Klausner is a Professor in Medicine and Public Health at the UCLA David Geffen School of Medicine. He is the former chief in the CDC’s infectious disease branch specializing in STI treatment and prevention.

Dr. Dan Marshak

Advisor

Dr. Dan Marshak is a Scientific Advisor to 5AM Ventures and is the former Chief Scientific Officer of PerkinElmer, a global leader in laboratory products and services and imaging equipment.

Dr. Joe Tam

Advisor

Dr. Joe Tam is the CEO of DiagCor, Hong Kong’s leading molecular diagnostic innovator and laboratory testing provider.


  • facebook
  • twitter
  • linkedin

contact us


+1 (657) 233-5880.

info@phasediagnostics.com

10527 Garden Grove Blvd, Garden Grove, CA, 92843